Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q96F25: Variant p.Pro65Leu

UDP-N-acetylglucosamine transferase subunit ALG14
Gene: ALG14
Feedback?
Variant information Variant position: help 65 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Proline (P) to Leucine (L) at position 65 (P65L, p.Pro65Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMS15; results in a severe reduction in protein expression; loss of function in dolichol-linked oligosaccharide biosynthetic process. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 65 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 216 The length of the canonical sequence.
Location on the sequence: help SGGHTTEILRLLGSLSNAYS P RHYVIADTDEMSANKINSFE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         SGGHTTEILRLLGSLSNA-YSPRHYVIADTDEMSANKINSF-E

Mouse                         SGGHTTEILRLVGSLSNA-YSPRHYVIAESDEMSAKKIHSL

Rat                           SGGHTAEILRLVGSLSGA-YSPRHYVIAESDEMSAKKIHSL

Baker's yeast                 SGGHTGEMIRLLENYQDLLLGKSIVYLGYSDEASRQRFAHF

Fission yeast                 SGGHTGEMLNLLNALDDKLYSVRSYVAGSDDTMSVSKASLL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 216 UDP-N-acetylglucosamine transferase subunit ALG14
Topological domain 25 – 216 Cytoplasmic



Literature citations
An in vitro assay for enzymatic studies on human ALG13/14 heterodimeric UDP-N-acetylglucosamine transferase.
Wang C.D.; Xu S.; Chen S.; Chen Z.H.; Dean N.; Wang N.; Gao X.D.;
Front. Cell Dev. Biol. 10:1008078-1008078(2022)
Cited for: FUNCTION; SUBUNIT; CHARACTERIZATION OF VARIANT CMS15 LEU-65; CHARACTERIZATION OF VARIANT MEPCA ASN-74; GLN-109 AND GLY-141; Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.
Cossins J.; Belaya K.; Hicks D.; Salih M.A.; Finlayson S.; Carboni N.; Liu W.W.; Maxwell S.; Zoltowska K.; Farsani G.T.; Laval S.; Seidhamed M.Z.; Donnelly P.; Bentley D.; McGowan S.J.; Muller J.; Palace J.; Lochmuller H.; Beeson D.; Donnelly P.; Bell J.; Bentley D.; McVean G.; Ratcfliffe P.; Taylor J.; Wilkie A.; Donnelly P.; Broxholme J.; Buck D.; Cazier J.B.; Cornall R.; Gregory L.; Knight J.; Lunter G.; McVean G.; Taylor J.; Tomlinson I.; Wilkie A.; Buck D.; Allan C.; Attar M.; Green A.; Gregory L.; Humphray S.; Kingsbury Z.; Lamble S.; Lonie L.; Pagnamenta A.; Piazza P.; Polanco G.; Trebes A.; McVean G.; Donnelly P.; Cazier J.B.; Broxholme J.; Copley R.; Fiddy S.; Grocock R.; Hatton E.; Holmes C.; Hughes L.; Humburg P.; Kanapin A.; Lise S.; Lunter G.; Martin H.; Murray L.; McCarthy D.; Rimmer A.; Sahgal N.; Wright B.; Yau C.;
Brain 136:944-956(2013)
Cited for: INVOLVEMENT IN CMS15; VARIANTS CMS15 LEU-65 AND 104-ARG--VAL-216 DEL; CHARACTERIZATION OF VARIANT CMS15 LEU-65;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.